Skip to main content

Bioanalysis Zone is part of Taylor & Francis Group.

  • Taylor & Francis
  • About us
  • Our journals
  • Our Digital Hubs

Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK.

Taylor & Francis
logo
 
  • Home
  • Awards
  • Events
  • Features
    • An Author's Perspective
    • Ask the Experts
    • Bioanalysis articles
    • Conference reports
    • eBooks
    • Expert opinion
    • In the Zone
    • Spotlights
    • Tech Digest
    • T&F journals

    Follow us on social media

  • Glossary
  • Topics
    • Applications
      • Advanced therapies
      • Biomarkers
      • Clinical
      • Diagnostics
      • Drug development
      • Forensics
      • Patient-centric sampling
      • Sports drug testing
      • Toxicology
      • Vaccines
    • Industry updates & regulations
      • Awareness
      • Biopharmaceuticals
      • Collaborations & mergers
      • Data processing and interpretation
      • Professional development
      • Regulated bioanalysis
    • Molecules
      • Antibodies | ADCs
      • Biosimilars
      • Large molecules
      • Metabolites
      • Oligonucleotides
      • Small molecules
    • Techniques
      • Automation
      • Biosensors
      • Chromatography
      • Flow Cytometry
      • Imaging
      • LBA
      • Microsampling
      • MS (LC–MS/MS, HRMS, IMS)
      • Sample preparation

    Follow us on social media

  • Multimedia
    • Coffee chats
    • Infographics
    • Interviews
    • Panel discussions
    • Podcasts
    • Videos
    • Webinars

    Follow us on social media

  • News
  • Partners
  • Register

Poster: Comparative metabolomics analysis of prostate cancer cells with different ethnic and tumorigenic phenotypes (Waters Corporation)

7 Oct 2014
General interest

A comprehensive high-throughput lipidomics and metabolomics analysis of prostate cancer cells with different tumorigenic phenotypes reveal potential markers for aggressive disease.

Click here to view poster

Related Links

  • Waters Corporation

Top content

  • Sun Pharma strikes deal for $11.75bn acquisition of Organon
  • More human relevant models: how ACMs, multiomics and AI are helping change drug discovery
  • $1B deal for SiranBio’s oligonucleotide candidate

Related tags

cancer high-throughput metabolomics
Previous article

Related articles

19 DEC 2013 MS (LC–MS/MS, HRMS, IMS)
Multiplatform approach important for metabolic fingerprinting
28 APR 2017 NEWS
Could metabolomic profiling lead to earlier diagnosis of H1N1 influenza pneumonia?
8 APR 2026 NEWS
A single test for multiple diseases
10 DEC 2013 GENERAL INTEREST
Zwitterionic immunobeads may serve as an effective tool in cancer diagnostics
2 MAR 2017 NEWS
Renal cell carcinoma could be distinguished from benign masses using metabolic profiles
1 JUN 2015 GENERAL INTEREST
First microfluidic device capable of capturing clusters of circulating tumor cells developed
  • About
  • Accessibility
  • Advertising & Sponsorship
  • Contact Us
  • Editorial Policies
  • Permissions
  • Whitelist Emails
  • Zone Leaders

Contact

Contact Us

Office info

Bioanalysis Zone is powered by Taylor & Francis Group

Bioanalysis Zone, 2-4 Park Square, Milton Park, Abingdon, Oxfordshire, OX14 4RN, United Kingdom
  • Taylor & Francis Group
  • Cookie Policy
  • Privacy Policy
  • Terms & Conditions
  • © 2026 Bioanalysis Zone